Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007, Article ID 83593, 14 pages
http://dx.doi.org/10.1155/2007/83593
Review Article

‘Striking the Right Balance’ in Targeting PPARγ in the Metabolic Syndrome: Novel Insights from Human Genetic Studies

Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK

Received 5 November 2006; Revised 13 December 2006; Accepted 13 December 2006

Academic Editor: Francine M. Gregoire

Copyright © 2007 Mark Gurnell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Olshansky, D. J. Passaro, and R. C. Hershow et al., “A potential decline in life expectancy in the United States in the 21st century,” New England Journal of Medicine, vol. 352, no. 11, pp. 1138–1145, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. C. L. Ogden, M. D. Carroll, L. R. Curtin, M. A. McDowell, C. J. Tabak, and K. M. Flegal, “Prevalence of overweight and obesity in the United States, 1999–2004,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1549–1555, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at PubMed
  4. J. Tuomilehto, J. Lindström, and J. G. Eriksson et al., “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance,” New England Journal of Medicine, vol. 344, no. 18, pp. 1343–1350, 2001. View at Publisher · View at Google Scholar
  5. W. C. Knowler, E. Barrett-Connor, and S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” New England Journal of Medicine, vol. 346, no. 6, pp. 393–403, 2002. View at Publisher · View at Google Scholar · View at PubMed
  6. J. Auwerx, “PPARγ, the ultimate thrifty gene,” Diabetologia, vol. 42, no. 9, pp. 1033–1049, 1999. View at Publisher · View at Google Scholar
  7. B. M. Forman, J. Chen, and R. M. Evans, “The peroxisome proliferator-activated receptors: ligands and activators,” Annals of the New York Academy of Sciences, vol. 804, pp. 266–275, 1996. View at Publisher · View at Google Scholar
  8. H. Yki-Järvinen, “Thiazolidinediones,” New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. J. A. Dormandy, B. Charbonnel, and D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macro vascular events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. DREAM trial investigators, “Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial,” The Lancet, vol. 368, no. 9541, pp. 1096–1105, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
  12. V. Fonseca, “Effect of thiazolidinediones on body weight in patients with diabetes mellitus,” American Journal of Medicine, vol. 115, no. 8, supplement 1, pp. 42–48, 2003. View at Publisher · View at Google Scholar
  13. T. M. Larsen, S. Toubro, and A. Astrup, “PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?,” International Journal of Obesity, vol. 27, no. 2, pp. 147–161, 2003. View at Publisher · View at Google Scholar · View at PubMed
  14. Y. Guan, C. Hao, and D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. S. Mudaliar, A. R. Chang, and R. R. Henry, “Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications,” Endocrine Practice, vol. 9, no. 5, pp. 406–416, 2003.
  16. I. Barroso, M. Gurnell, and V. E. F. Crowley et al., “Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, no. 6764, pp. 880–883, 1999. View at Publisher · View at Google Scholar · View at PubMed
  17. A. K. Agarwal and A. Garg, “A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 408–411, 2002. View at Publisher · View at Google Scholar
  18. R. A. Hegele, H. Cao, C. Frankowski, S. T. Mathews, and T. Leff, “PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy,” Diabetes, vol. 51, no. 12, pp. 3586–3590, 2002. View at Publisher · View at Google Scholar
  19. D. B. Savage, G. D. Tan, and C. L. Acerini et al., “Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ,” Diabetes, vol. 52, no. 4, pp. 910–917, 2003. View at Publisher · View at Google Scholar
  20. D. B. Savage, M. Agostini, and I. Barroso et al., “Digenic inheritance of severe insulin resistance in a human pedigree,” Nature Genetics, vol. 31, no. 4, pp. 379–384, 2002. View at Publisher · View at Google Scholar · View at PubMed
  21. G. A. Francis, G. Li, and R. Casey et al., “Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3),” BMC Medical Genetics, vol. 7, p. 3, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. R. A. Hegele, E. Ur, T. P. Ransom, and H. Cao, “A frameshift mutation in peroxisome-proliferator-activated receptor-γ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367),” Clinical Genetics, vol. 70, no. 4, pp. 360–362, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. M. Agostini, E. Schoenmakers, and C. Mitchell et al., “Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance,” Cell Metabolism, vol. 4, no. 4, pp. 303–311, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. H.-P. Guan, T. Ishizuka, P. C. Chui, M. Lehrke, and M. A. Lazar, “Corepressors selectively control the transcriptional activity of PPARγ in adipocytes,” Genes and Development, vol. 19, no. 4, pp. 453–461, 2005. View at Publisher · View at Google Scholar · View at PubMed
  25. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. L. Fajas, D. Auboeuf, and E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar
  28. L. Fajas, J.-C. Fruchart, and J. Auwerx, “PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998. View at Publisher · View at Google Scholar
  29. H. Sundvold and S. Lien, “Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 383–390, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  31. I. Tzameli, H. Fang, and M. Ollero et al., “Regulated production of a peroxisome proliferator-activated receptor-γ ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes,” Journal of Biological Chemistry, vol. 279, no. 34, pp. 36093–36102, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. E. D. Rosen, C.-H. Hsu, and X. Wang et al., “C/EBPα induces adipogenesis through PPARγ: a unified pathway,” Genes and Development, vol. 16, no. 1, pp. 22–26, 2002. View at Publisher · View at Google Scholar · View at PubMed
  33. P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994. View at Publisher · View at Google Scholar
  34. Y. Barak, M. C. Nelson, and E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar
  35. E. D. Rosen, P. Sarraf, and A. E. Troy et al., “PPARγ is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999. View at Publisher · View at Google Scholar
  36. N. Kubota, Y. Terauchi, and H. Miki et al., “PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999. View at Publisher · View at Google Scholar
  37. M. Gurnell, J. M. Wentworth, and M. Agostini et al., “A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis,” Journal of Biological Chemistry, vol. 275, no. 8, pp. 5754–5759, 2000. View at Publisher · View at Google Scholar
  38. H. Bays, L. Mandarino, and R. A. DeFronzo, “Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 463–478, 2004. View at Publisher · View at Google Scholar
  39. M. Adams, C. T. Montague, and J. B. Prins et al., “Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation,” Journal of Clinical Investigation, vol. 100, no. 12, pp. 3149–3153, 1997.
  40. M. Ristow, D. Müller-Wieland, A. Pfeiffer, W. Krone, and C. R. Kahn, “Obesity associated with a mutation in a genetic regulator of adipocyte differentiation,” New England Journal of Medicine, vol. 339, no. 14, pp. 953–959, 1998. View at Publisher · View at Google Scholar
  41. E. Hu, J. B. Kim, P. Sarraf, and B. M. Spiegelman, “Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ,” Science, vol. 274, no. 5295, pp. 2100–2103, 1996. View at Publisher · View at Google Scholar
  42. M. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, “Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site,” Journal of Biological Chemistry, vol. 272, no. 8, pp. 5128–5132, 1997. View at Publisher · View at Google Scholar
  43. M. Blüher and R. Paschke, “Analysis of the relationship between PPAR-γ 2 gene variants and severe insulin resistance in obese patients with impaired glucose tolerance,” Experimental and Clinical Endocrinology and Diabetes, vol. 111, no. 2, pp. 85–90, 2003.
  44. M. Agostini, M. Gurnell, and D. B. Savage et al., “Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ,” Endocrinology, vol. 145, no. 4, pp. 1527–1538, 2004. View at Publisher · View at Google Scholar · View at PubMed
  45. K. Al-Shali, H. Cao, N. Knoers, A. R. Hermus, C. J. Tack, and R. A. Hegele, “A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5655–5660, 2004. View at Publisher · View at Google Scholar · View at PubMed
  46. Y.-S. Tsai, H.-J. Kim, and N. Takahashi et al., “Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 240–249, 2004. View at Publisher · View at Google Scholar
  47. S. L. Gray, E. D. Nora, and J. Grosse et al., “Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor γ function (P465L PPARγ) in mice,” Diabetes, vol. 55, no. 10, pp. 2669–2677, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. S. S. Deeb, L. Fajas, and M. Nemoto et al., “A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at PubMed
  49. M. Stumvoll and H. Häring, “The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism,” Diabetes, vol. 51, no. 8, pp. 2341–2347, 2002. View at Publisher · View at Google Scholar
  50. M. M. Swarbrick, C. M. L. Chapman, B. M. McQuillan, J. Hung, P. L. Thompson, and J. P. Beilby, “A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-γ2 is associated with combined hyperlipidaemia in obesity,” European Journal of Endocrinology, vol. 144, no. 3, pp. 277–282, 2001. View at Publisher · View at Google Scholar
  51. B. A. Beamer, C.-J. Yen, and R. E. Andersen et al., “Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations,” Diabetes, vol. 47, no. 11, pp. 1806–1808, 1998. View at Publisher · View at Google Scholar
  52. S. Masud and S. Ye, “Effect of the peroxisome proliferates activated receptor-γ gene Pro12Ala variant on body mass index: a meta-analysis,” Journal of Medical Genetics, vol. 40, no. 10, pp. 773–780, 2003. View at Publisher · View at Google Scholar
  53. J. Luan, P. O. Browne, and A.-H. Harding et al., “Evidence for gene-nutrient interaction at the PPARγ locus,” Diabetes, vol. 50, no. 3, pp. 686–689, 2001. View at Publisher · View at Google Scholar
  54. J. Robitaille, J.-P. Després, L. Pérusse, and M.-C. Vohl, “The PPAR-γ P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec family study,” Clinical Genetics, vol. 63, no. 2, pp. 109–116, 2003. View at Publisher · View at Google Scholar
  55. T. M. Willson, J. E. Cobb, and D. J. Cowan et al., “The structure—activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at PubMed
  56. R. Mukherjee, P. J. A. Davies, and D. L. Crombie et al., “Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists,” Nature, vol. 386, no. 6623, pp. 407–410, 1997. View at Publisher · View at Google Scholar · View at PubMed
  57. S. M. Rangwala, B. Rhoades, and J. S. Shapiro et al., “Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity,” Developmental Cell, vol. 5, no. 4, pp. 657–663, 2003. View at Publisher · View at Google Scholar
  58. W. He, Y. Barak, and A. Hevener et al., “Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15712–15717, 2003. View at Publisher · View at Google Scholar · View at PubMed
  59. A. L. Hevener, W. He, and Y. Barak et al., “Muscle-specific Pparg deletion causes insulin resistance,” Nature Medicine, vol. 9, no. 12, pp. 1491–1497, 2003. View at Publisher · View at Google Scholar · View at PubMed
  60. A. W. Norris, L. Chen, and S. J. Fisher et al., “Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 608–618, 2003. View at Publisher · View at Google Scholar · View at PubMed
  61. K. Matsusue, M. Haluzik, and G. Lambert et al., “Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 737–747, 2003. View at Publisher · View at Google Scholar
  62. J. C. Florez, J. Hirschhorn, and D. Altshuler, “The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits,” Annual Review of Genomics and Human Genetics, vol. 4, pp. 257–291, 2003. View at Publisher · View at Google Scholar · View at PubMed
  63. A. Memisoglu, F. B. Hu, and S. E. Hankinson et al., “Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARγ gene and type 2 diabetes,” Diabetes Care, vol. 26, no. 10, pp. 2915–2917, 2003. View at Publisher · View at Google Scholar
  64. E. S. Tai, D. Corella, and M. Deurenberg-Yap et al., “Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population,” Journal of Lipid Research, vol. 45, no. 4, pp. 674–685, 2004. View at Publisher · View at Google Scholar · View at PubMed
  65. A. S. F. Doney, B. Fischer, and J. E. Cecil et al., “Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to type 2 diabetes,” Diabetologia, vol. 47, no. 3, pp. 555–558, 2004. View at Publisher · View at Google Scholar · View at PubMed
  66. L. Chao, B. Marcus-Samuels, and M. M. Mason et al., “Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1221–1228, 2000.
  67. K. Schoonjans, J. Peinado-Onsurbe, and A.-M. Lefebvre et al., “PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996.
  68. B. I. Frohnert, T. Y. Hui, and D. A. Bernlohr, “Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene,” Journal of Biological Chemistry, vol. 274, no. 7, pp. 3970–3977, 1999. View at Publisher · View at Google Scholar
  69. H.-P. Guan, Y. Li, M. V. Jensen, C. B. Newgard, C. M. Steppan, and M. A. Lazar, “A futile metabolic cycle activated in adipocytes by antidiabetic agents,” Nature Medicine, vol. 8, no. 10, pp. 1122–1128, 2002. View at Publisher · View at Google Scholar · View at PubMed
  70. J. Tordjman, G. Chauvet, J. Quette, E. G. Beale, C. Forest, and B. Antoine, “Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells,” Journal of Biological Chemistry, vol. 278, no. 21, pp. 18785–18790, 2003. View at Publisher · View at Google Scholar · View at PubMed
  71. O. Vaccaro, F. P. Mancini, and G. Ruffa et al., “Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ2 gene in healthy individuals,” Clinical Endocrinology, vol. 57, no. 4, pp. 481–486, 2002. View at Publisher · View at Google Scholar
  72. P. Peraldi, M. Xu, and B. M. Spiegelman, “Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling,” Journal of Clinical Investigation, vol. 100, no. 7, pp. 1863–1869, 1997.
  73. C. M. Steppan, S. T. Bailey, and S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at PubMed
  74. Q. Yang, T. E. Graham, and N. Mody et al., “Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes,” Nature, vol. 436, no. 7049, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at PubMed
  75. N. Maeda, M. Takahashi, and T. Funahashi et al., “PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–2099, 2001. View at Publisher · View at Google Scholar
  76. R. S. Ahima and J. S. Flier, “Adipose tissue as an endocrine organ,” Trends in Endocrinology and Metabolism, vol. 11, no. 8, pp. 327–332, 2000. View at Publisher · View at Google Scholar
  77. T. P. Combs, J. A. Wagner, and J. Berger et al., “Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization,” Endocrinology, vol. 143, no. 3, pp. 998–1007, 2002. View at Publisher · View at Google Scholar
  78. R. K. Semple, M. A. Soos, and J. Luan et al., “Elevated plasma adiponectin in humans with genetically defective insulin receptors,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3219–3223, 2006. View at Publisher · View at Google Scholar · View at PubMed
  79. M. Iwata, T. Haruta, and I. Usui et al., “Pioglitazone ameliorates tumor necrosis factor-α-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ,” Diabetes, vol. 50, no. 5, pp. 1083–1092, 2001. View at Publisher · View at Google Scholar
  80. U. Smith, S. Gogg, A. Johansson, T. Olausson, V. Rotter, and B. Svalstedt, “Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes,” FASEB Journal, vol. 15, no. 1, pp. 215–220, 2001. View at Publisher · View at Google Scholar · View at PubMed
  81. J. Rieusset, C. Chambrier, and K. Bouzakri et al., “The expression of the p85α subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor γ in human adipocytes,” Diabetologia, vol. 44, no. 5, pp. 544–554, 2001. View at Publisher · View at Google Scholar
  82. V. Ribon, J. H. Johnson, H. S. Camp, and A. R. Saltiel, “Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14751–14756, 1998. View at Publisher · View at Google Scholar
  83. C. A. Baumann, N. Chokshi, A. R. Saltiel, and V. Ribon, “Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene,” Journal of Biological Chemistry, vol. 275, no. 13, pp. 9131–9135, 2000. View at Publisher · View at Google Scholar
  84. I. J. Bujalska, S. Kumar, and P. M. Stewart, “Does central obesity reflect “Cushing's disease of the omentum”?,” The Lancet, vol. 349, no. 9060, pp. 1210–1213, 1997. View at Publisher · View at Google Scholar
  85. H. Masuzaki, J. Paterson, and H. Shinyama et al., “A transgenic model of visceral obesity and the metabolic syndrome,” Science, vol. 294, no. 5549, pp. 2166–2170, 2001. View at Publisher · View at Google Scholar · View at PubMed
  86. J. Berger, M. Tanen, and A. Elbrecht et al., “Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity,” Journal of Biological Chemistry, vol. 276, no. 16, pp. 12629–12635, 2001. View at Publisher · View at Google Scholar · View at PubMed
  87. B. S. Cha, T. P. Ciaraldi, and L. Carter et al., “Peroxisome proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle,” Diabetologia, vol. 44, no. 4, pp. 444–452, 2001. View at Publisher · View at Google Scholar
  88. C. Kausch, J. Krützfeldt, and A. Witke et al., “Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells,” Biochemical and Biophysical Research Communications, vol. 280, no. 3, pp. 664–674, 2001. View at Publisher · View at Google Scholar · View at PubMed
  89. A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca, “Nonhypoglycemic effects of thiazolidinediones,” Annals of Internal Medicine, vol. 134, no. 1, pp. 61–71, 2001.
  90. F. Massiéra, M. Bloch-Faure, and D. Ceiler et al., “Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation,” The FASEB Journal, vol. 15, no. 14, pp. 2727–2729, 2001. View at Publisher · View at Google Scholar · View at PubMed
  91. C. J. Östgren, U. Lindblad, O. Melander, A. Melander, L. Groop, and L. Rȧstam, “Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project,” Journal of Hypertension, vol. 21, no. 9, pp. 1657–1662, 2003.
  92. S. J. Hasstedt, Q.-F. Ren, K. Teng, and S. C. Elbein, “Effect of the peroxisome proliferator-activated receptor-γ2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 536–541, 2001. View at Publisher · View at Google Scholar
  93. B. Isomaa, P. Almgren, and T. Toumi et al., “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001. View at Publisher · View at Google Scholar
  94. J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama, “Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 5, pp. 1818–1820, 1998. View at Publisher · View at Google Scholar
  95. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar
  96. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar
  97. M. Ricote, J. Huang, and L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Publisher · View at Google Scholar
  98. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at PubMed
  99. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at PubMed
  100. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar · View at PubMed
  101. K. J. Moore, E. D. Rosen, and M. L. Fitzgerald et al., “The role of PPAR-γ in macrophage differentiation and cholesterol uptake,” Nature Medicine, vol. 7, no. 1, pp. 41–47, 2001. View at Publisher · View at Google Scholar · View at PubMed
  102. A. R. Tall, P. Costet, and N. Wang, “Regulation and mechanisms of macrophage cholesterol efflux,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 899–904, 2002. View at Publisher · View at Google Scholar
  103. G. Chinetti, S. Lestavel, and V. Bocher et al., “PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001. View at Publisher · View at Google Scholar · View at PubMed
  104. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar · View at PubMed
  105. E. Iwata, I. Yamamoto, and T. Motomura et al., “The association of Pro12Ala polymorphism in PPARγ2 with lower carotid artery IMT in Japanese,” Diabetes Research and Clinical Practice, vol. 62, no. 1, pp. 55–59, 2003. View at Publisher · View at Google Scholar
  106. Z. C. Yan, Z. M. Zhu, and C. Y. Shen et al., “Peroxisome proliferator-activated receptor γ C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome,” Zhonghua Yi Xue Za Zhi, vol. 84, no. 7, pp. 543–547, 2004 (Chinese).
  107. Y. Li and M. A. Lazar, “Differential gene regulation by PPARγ agonist and constitutively active PPARγ2,” Molecular Endocrinology, vol. 16, no. 5, pp. 1040–1048, 2002. View at Publisher · View at Google Scholar
  108. M. J. Reginato, S. T. Bailey, and S. L. Krakow et al., “A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32679–32684, 1998. View at Publisher · View at Google Scholar
  109. S. Rocchi, F. Picard, and J. Vamecq et al., “A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity,” Molecular Cell, vol. 8, no. 4, pp. 737–747, 2001. View at Publisher · View at Google Scholar
  110. A. Shimaya, E. Kurosaki, R. Nakano, R. Hirayama, M. Shibasaki, and H. Shikama, “The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice,” Metabolism: Clinical and Experimental, vol. 49, no. 3, pp. 411–417, 2000.
  111. P. Misra, R. Chakrabarti, and R. K. Vikramadithyan et al., “PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 763–771, 2003. View at Publisher · View at Google Scholar · View at PubMed
  112. J. P. Berger, A. E. Petro, and K. L. MacNaul et al., “Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator,” Molecular Endocrinology, vol. 17, no. 4, pp. 662–676, 2003. View at Publisher · View at Google Scholar · View at PubMed
  113. K. R. Kim, J. H. Lee, and S. J. Kim et al., “KR-62980: a novel peroxisome proliferator-activated receptor γ agonist with weak adipogenic effects,” Biochemical Pharmacology, vol. 72, no. 4, pp. 446–454, 2006. View at Publisher · View at Google Scholar · View at PubMed
  114. K. Liu, R. M. Black, and J. J. Acton III et al., “Selective PPARγ modulators with improved pharmacological profiles,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 10, pp. 2437–2440, 2005. View at Publisher · View at Google Scholar · View at PubMed